Landscape Capital Management L.L.C. Purchases Shares of 30,054 Abivax SA Sponsored ADR $ABVX

Landscape Capital Management L.L.C. purchased a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 30,054 shares of the company’s stock, valued at approximately $4,053,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Prosight Management LP acquired a new position in Abivax in the fourth quarter valued at approximately $2,293,000. FORA Capital LLC acquired a new position in Abivax in the fourth quarter valued at approximately $1,060,000. The Manufacturers Life Insurance Company lifted its stake in Abivax by 36.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 35,532 shares of the company’s stock valued at $4,915,000 after buying an additional 9,396 shares during the period. Affinity Asset Advisors LLC lifted its stake in Abivax by 40.3% in the fourth quarter. Affinity Asset Advisors LLC now owns 505,000 shares of the company’s stock valued at $68,102,000 after buying an additional 145,000 shares during the period. Finally, Stifel Financial Corp acquired a new position in Abivax in the fourth quarter valued at approximately $1,380,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have issued reports on ABVX. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Barclays boosted their price target on Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. Morgan Stanley dropped their price target on Abivax from $145.00 to $132.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 2nd. Truist Financial dropped their price target on Abivax from $140.00 to $135.00 and set a “buy” rating on the stock in a research note on Tuesday, June 2nd. Finally, Wedbush raised Abivax from an “underperform” rating to a “neutral” rating and dropped their price target for the company from $110.00 to $90.00 in a research note on Tuesday, June 2nd. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Abivax presently has a consensus rating of “Moderate Buy” and a consensus target price of $130.08.

Abivax Trading Down 4.3%

NASDAQ ABVX opened at $96.55 on Friday. The firm has a market capitalization of $7.69 billion, a P/E ratio of -18.53 and a beta of 0.69. The business has a fifty day simple moving average of $116.01 and a 200 day simple moving average of $119.12. Abivax SA Sponsored ADR has a 12 month low of $5.69 and a 12 month high of $148.83.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. As a group, sell-side analysts predict that Abivax SA Sponsored ADR will post -3.4 EPS for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.